Supernus v. Aurobindo: Qelbree® Viloxazine Patent Infringement — Consolidated
Supernus Pharmaceuticals filed suit in the District of New Jersey against Aurobindo Pharma asserting six patents covering Qelbree® viloxazine extended-release capsules (100 mg, 150 mg, 200 mg). The case was consolidated with seven related actions into a single master proceeding within 180 days of filing, covering one of the most closely watched ADHD drug patent portfolios in current Hatch-Waxman litigation.
Six-Patent Qelbree® ANDA Battle Absorbed into NJ Master Docket
Supernus Pharmaceuticals, Inc. — holder of an extensive patent portfolio covering viloxazine extended-release oral capsules marketed as Qelbree® — filed this infringement action against Indian generic manufacturer Aurobindo Pharma, Ltd. in the District of New Jersey on 26 June 2025. The complaint asserted six granted U.S. patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2, spanning formulation, composition, and method-of-use claims tied to the 100 mg, 150 mg, and 200 mg dosage strengths of Qelbree®.
The case did not proceed to a merits ruling. On 23 December 2025, the court issued an order consolidating this action — along with seven related civil actions (Nos. 25-12184, 25-12188, 25-13201, 25-13204, 25-13207, 25-15399, and 25-18683) — into a single master proceeding under Civil Action No. 25-12183. All counsel admitted in the individual actions, including those admitted pro hac vice, were deemed admitted in the consolidated action. The basis of termination is therefore consolidation, not dismissal or settlement.
The 180-day period from filing to consolidation order is consistent with efficient ANDA multi-defendant docket management in the District of New Jersey, which regularly consolidates parallel Paragraph IV suits against multiple generic filers. The public record is silent on whether any 30-month stay has been triggered, whether any licensing discussions have commenced, or the scope of claim construction disputes that will define the consolidated proceedings. The breadth of the six-patent assertion — covering at least two independent patent families — suggests Supernus is pursuing a layered enforcement strategy typical of blockbuster CNS drug defence.
Filing to Case Consolidated in 180 days
180 days to consolidation — faster than the typical ANDA district court case timeline
Case consolidated: what the transfer to master docket means for both parties
Consolidation absorbs individual case — no merits adjudication
Consolidation under Fed. R. Civ. P. 42(a) merges procedurally related actions before the same court into a single coordinated proceeding. This case (25-12186) has been subsumed into master action 25-12183 alongside seven parallel suits. No claim construction, no liability finding, and no damages ruling has been made. All prior appearances and pro hac vice admissions carry over automatically per the court’s order.
No merits rulingSupernus gains consolidated docket — litigation efficiency advantage
Consolidation typically benefits the patent holder in multi-defendant ANDA disputes. Supernus can now pursue claim construction, discovery, and trial preparation in a single coordinated proceeding against all generic challengers simultaneously, reducing duplicative effort and risk of inconsistent rulings across parallel dockets. The six-patent assertion remains live and fully in force within the consolidated action.
Six patents remain assertedAurobindo faces coordinated multi-defendant proceedings
Aurobindo Pharma now litigates alongside other generic filers in a single consolidated action. While consolidation can allow co-defendants to share discovery and expert costs, it also means Aurobindo’s ANDA approval timeline is linked to the pace of the master proceeding. A 30-month regulatory stay, if triggered, continues to run regardless of consolidation. The public record does not disclose whether Aurobindo has filed an IPR petition on any of the six asserted patents.
ANDA timeline at riskQelbree® market exclusivity dispute moves to centralised arena
With eight related actions now consolidated, the outcome of the master proceeding will determine generic entry timing for all Paragraph IV filers simultaneously. Qelbree® is a non-stimulant ADHD treatment with significant commercial value in the CNS market. A single consolidated validity and infringement ruling across six patents creates high-stakes, winner-takes-all dynamics that typically increase settlement pressure on all parties as trial approaches.
High-stakes consolidated trialFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | CNS-focused specialty pharma — holder of US12121523B2 and 5 further Qelbree® patentsSearch in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Aurobindo Pharma, Ltd. — Indian generic pharmaceutical manufacturer and ANDA filerSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | AARON S. LUKAS | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | GENG HUA | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kaan Ekiner | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | KERI L. SCHAUBERT | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | W. BLAKE COBLENTZ | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | COUNSEL NOT ADMITTED TO USDC — NJ BAR | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | COZEN O’CONNOR | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order does not constitute a merits ruling on infringement or validity. Its operative effect is procedural: all individual dockets are subsumed into master action No. 25-12183, and all counsel admissions transfer automatically. The order’s enumeration of eight civil actions confirms the breadth of parallel generic challenges Supernus is managing simultaneously, which is consistent with a well-resourced Hatch-Waxman enforcement campaign across multiple ANDA filers for a commercially significant CNS product.
US12121523B2 — Viloxazine extended-release oral capsule formulations
The six asserted patents — spanning application numbers US13/761757 through US17/896774 — collectively cover the formulation science, composition, and therapeutic use of viloxazine in an extended-release oral capsule format. Viloxazine is a selective norepinephrine reuptake inhibitor repositioned by Supernus as a non-stimulant ADHD treatment. The patent family’s priority dates suggest a sustained prosecution strategy beginning with early composition filings and extending through later continuation applications that protect incremental formulation refinements and specific dosage strengths.
The breadth of the six-patent assertion is strategically significant. By asserting patents with different claim scopes — covering composition, formulation process, and method-of-use — Supernus creates multiple independent barriers to generic entry. For competitors and ANDA filers, this means a design-around or IPR strategy must address each claim category independently. In the CNS drug market, where non-stimulant ADHD options command premium pricing, the commercial stakes of these patents are substantial and the enforcement posture is consistent with a long-duration exclusivity defence.
Should you run an FTO against the Qelbree® viloxazine patent portfolio?
Any company developing, manufacturing, or seeking ANDA approval for a viloxazine extended-release oral capsule product in the 100–200 mg dosage range should treat the six Supernus patents as active blocking rights. The consolidated New Jersey litigation confirms these patents are being actively enforced against multiple filers. R&D teams working on non-stimulant ADHD formulations, novel release mechanisms, or viloxazine analogues should also assess claim scope, as method-of-use claims may capture therapeutic indications beyond the specific Qelbree® label.
PatSnap Eureka’s FTO Search Agent can map all six asserted patents against your product’s formulation parameters, identify which specific claims present the highest blocking risk, and surface any pending continuation applications in the Supernus viloxazine family that may issue after a generic launch decision. Eureka’s citation network analysis can also identify IPR petitions, inter partes proceedings, or prosecution history estoppel arguments that may limit claim scope — critical intelligence before any ANDA filing or product development commitment.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases: viloxazine & CNS drug patent disputes
Related Paragraph IV patent infringement actions involving CNS drug formulations litigated in the District of New Jersey, including parallel Qelbree® consolidated actions.
What this case signals for the CNS pharma ANDA IP landscape
The Qelbree® consolidation is a textbook example of layered ANDA patent defence strategy unfolding in real time.
Six-patent stacking raises the bar for Paragraph IV certification
Asserting six patents across formulation, composition, and method-of-use claims forces generic challengers to invalidate or design around each independently. Even a single surviving patent can block generic entry. Companies monitoring the Qelbree® ANDA space should track IPR petition activity against all six asserted patents, as inter partes review remains the most viable route to early invalidity.
NJ District Court consolidation signals coordinated enforcement playbook
The District of New Jersey’s consolidation of eight parallel ANDA actions within six months of the first filing reflects an increasingly common judicial efficiency strategy. IP teams at generic manufacturers should anticipate that multi-defendant consolidation will compress individual case timelines and increase pressure to resolve or settle before the master proceeding reaches claim construction.
Supernus v Aurobindo — key questions answered
Consolidation means Case No. 25-12186 was merged into master action No. 25-12183 under Fed. R. Civ. P. 42(a). No merits ruling on infringement or validity was issued. All counsel admissions carry over, and future litigation — including claim construction and trial — will proceed in the consolidated docket. The case is closed as a standalone action but the dispute continues in the master proceeding.
Supernus asserted six U.S. patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. These cover viloxazine extended-release capsule formulations, compositions, and methods of use corresponding to the 100 mg, 150 mg, and 200 mg dosage strengths of Qelbree®.
Eight civil actions in total were consolidated into master docket No. 25-12183, including Case Nos. 25-12184, 25-12186, 25-12188, 25-13201, 25-13204, 25-13207, 25-15399, and 25-18683. This suggests Supernus is litigating against multiple generic ANDA filers simultaneously in a coordinated enforcement campaign.
Consolidation is a procedural case management tool and does not alter the Hatch-Waxman 30-month stay, which runs from the date the relevant NDA holder or patent owner received notice of the Paragraph IV certification. Each filer’s stay period is calculated independently based on their certification notice date. The public record for this case does not disclose the specific stay expiry dates for each consolidated defendant.
Viloxazine is a selective norepinephrine reuptake inhibitor approved by the FDA as Qelbree® for ADHD treatment in paediatric and adult patients. As a non-stimulant ADHD medication, it competes in a market segment with significant commercial value and limited generic alternatives. The six-patent portfolio spanning formulation and method-of-use claims represents Supernus’s strategy to maintain market exclusivity against multiple generic challengers simultaneously.
PatSnap Eureka searches patents and litigation data to answer instantly.